[Clinical investigation of interferons in the preleukemic state (CML and XXXX )].

@entity1 @entity4289 @entity7139 @entity417 @entity12188 @entity1778 @entity1860
We treated 11 @entity1 who had @entity1860 with natural interferon alpha ( @entity1 lymphoblastoid interferon; HLBI). HLBI was given at 6-12 X 10(6) u/day i.m. or i.s.c. during induction therapy. Nine @entity1 responded to the treatment, of whom 7 had hematologic remission and 2 had partial remission. Six @entity1 with @entity4289 or @entity1778 , and 3 @entity1 with @entity1778 from @entity4289 were treated with recombinant interferon gamma (GI-3). GI-3 was given at 0.4 X 10(6) u/m2 of body-surface area per day i.s.c. or i.v. for 4-6 weeks. In 2 @entity1 with @entity7139 and @entity1778 , the blast cell count in bone marrow decreased from 8-16% to 2-3% after 4 weeks of administration. In another @entity1 with @entity1778 , blast cells in the marrow did not decrease, but @entity417 was improved without transfusion, increasing the bone marrow NCC and erythroblast count. In @entity1 with @entity1778 and @entity12188 , no clinical effect was obtained. Interferons can therefore be offered to @entity1 in a preleukemic state.
